KURA Troy Edward Wilson bought Kura Oncology, Inc. shares — SEC Form 4BUYKura Oncology, Inc.

The stock is trading 15.69% below its 52-week high of $12.49, having gained 17.59% over the last 90 days despite a 3.04% decline in the past 30 days.

• •Q2 2026 earnings on August 13, 2026, following a revenue beat of +23.61% and earnings beat of +13.48% in the prior quarter.
• •Upcoming presentation of updated Phase 1a FIT-001 trial data at the 2026 Kidney Cancer Research Summit.
• •Russell growth index reclassification, which may alter the company's risk profile and attract passive index fund inflows.

• •The stock is currently short 15.22% of its float, indicating significant bearish sentiment that could pressure the price.
• •The company reported a net loss of -$4.904348 in its forward P/E ratio, reflecting ongoing financial challenges.